Thursday, September 10, 2009

8:00 – 8:30

Continental Breakfast

8:30 - 8:45

Onco-Biotechnology Summit - Welcoming Remarks

Steven T. Rosen, MD, FACP, Director, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Alicia Löffler, Ph.D.,  Director and Professor, Kellogg Center for Biotechnology

8:45 – 10:00

Panel:  Challenges of Developing a Biotechnology Product:  Pharma vs. Biotech Approach

Moderator:  Raymond C. Bergan, MD, Director, Experimental Therapeutics at Robert H. Lurie Comprehensive Cancer Center

Thomas F. Bumol, Ph.D., VP of biotechnology discovery research Eli Lilly and Company and serves as president of Applied Molecular Evolution, a subsidiary of Eli Lilly and Company

John Leonard, M.D., vice president, Global Pharmaceutical Research and Development, Abbott

Stephen A. Sherwin, M.D., Chairman and Chief Executive Officer of Cell Genesys, Inc

Robert Justice, M.D., Director of the Division of Drug Oncology Products in the Office of Oncology Drug Products at the Food and Drug Administration

10:00 – 11:15

Panel:  Ownership of Resources - Talent, IP, Equity & Leadership: Moving from Science to Commercial Model

Moderator:  Alicia Löffler, Ph.D.,  Director and Professor Kellogg Center for Biotechnology

Katharine Ku, Director, Office of Technology Licensing at Stanford University
Jane Fischer, Baxter International Inc.

Michael J. Cleare, Ph.D., Associate Vice Provost for Research and Executive Director, Center for Technology Transfer at the University of Pennsylvania

Pharma or VC representative

11:15 – 11:30

Break

11:30 – 12:45

Panel:  Streamlining and Improving Clinical Trial Policies, Contracts and Execution

Moderator:  Al B. Benson III, MD Associate Director for Clinical Investigations at the Robert H. Lurie Comprehensive Cancer Center at Northwestern and Chair of NCCN Board of Directors

Senator Herb Kohl of Wisconsin

Alan F. Eisenberg Executive Vice President for Emerging Companies and Business Development at the Biotechnology Industry Organization (BIO).

Gregory Curt, M.D., U.S. senior medical lead, AstraZeneca

12:45 – 1:30

Lunch

1:30 – 2:15

Keynote Presentation: Public Interest Considerations in Academic and Industry Relationships

Ezekiel Emanuel, MD, PhD  Chair  Department of Bioethics NIH Clinical Center – to be invited

2:15 – 3:30

Panel:  Evidence Based Medicine and Clinical Trials:  Incorporating Economic and Other Assessments into Clinical Development

Moderator:  William J. Gradishar, MD

Carol J. McCall, FSA, MAAA, VP, Research and Development, Humana Inc.

FDA representative

Susan Guba, MDMedical Advisor at Eli Lilly

3:30 – 3:45

Break

3:45 – 5:00

Panel:  Standardizing Use of Oncology Guidelines Across Health Systems and Private Practices: Benefits and Challenges

William T. McGivney, Ph.D., Chief Executive Officer of the National Comprehensive Cancer Network (NCCN)

Joseph S. Bailes, MD, Executive Vice President of Clinical Affairs for US Oncology in Houston and a past president of the American Society of Clinical Oncology (ASCO)

Robert W Carlson, MD , Head of Breast Cancer Oncology Clinic at Stanford

Michael W. Rosen, M.D., National Medical Director - OptumHealth Care Solutions of UnitedHealth Group

5:00 – 6:30

Networking Reception

Friday, September 11, 2009

8:00 – 8:30

Continental Breakfast

8:30 – 9:45

Panel:  Disruptive Medical Innovations: Rethinking the Product Discovery, Development and Adoption Model

Moderator:  Teresa Woodruff, Ph.D.,  Northwestern University, Feinberg School of Medicine; Oncofertility Consortium

Laurie Zoloth, PhD, Director of Center for Bioethics, Science and Society, Feinberg School of Medicine

Stephen Albert Johnston, Ph.D., Director, Center for Innovations in Medicine at The Biodesign Institute at Arizona State University

Mike Heslop, senior vice president and general manager of Genzyme's endocrine business (Thyrogen)  

9:45 – 11:00

Panel:  The Future Role of Patient Advocacy in Developing Health Solutions

Moderator:  Daniel Diermeier, Ph.D.; Kellogg Professor and Director of the Ford Motor Company Center for Global Citizenship

Shobita Parthasarathy, Ph.D.; Co-Director of the Science, Technology, and Public Policy Program at the Gerald R. Ford School of Public Policy at the University of Michigan

Elliott D. Hillback, Jr., Senior Vice President, Corporate Affairs Genzyme

Michael Werner, lymphoma patient and Board member of the Lymphoma Research Foundation

11:00 – 11:15

Break

11:15 – 12:15

Keynote Presentation: 

Mark B. McClellan, Director, Engelberg Center for Health Care Reform at The Brookings Institution

12:15 – 12:45

Lunch

12:45 – 2:00

Panel:  Preserving Quality of Oncology Care in the Era of Health Cost Containment

Moderator:  Julian C. Schink, MD Northwestern University

Joanne C. Armstrong, M.D. Senior Medical Director for Women's Health and Clinical Lead for Genomics Aetna

Paul Boulis, President, Blue Cross Blue Shield of Illinois

Jackie Garner, Regional Administrator , Region V, Centers for Medicare & Medicaid Services

2:00 – 3:15

Panel:  Approaches to Addressing Long Term Public Safety of Biotechnology in Oncology

Moderator:  Charles L. Bennett, MD, PhD - Northwestern University

Michael Wolf  PhD, Northwestern University’s Feinberg School of Medicine

Linda Emanuel, MD, Ph.D.; Director Buehler Center on Aging, Health & Society

Stan Blaylock, President of Walgreen’s Health Services, the managed care division of Walgreen Co

Robert Epstein, MD, Chief Medical Officer - Medco

3:15 – 3:30

Break

3:30 – 4:45

Case Study: A Pilot of an Innovative Care and Reimbursement Model in Breast Cancer

Moderator:  Julia Trosman, Executive Director Center for Business Models in Healthcare

Nora M. Hansen, MD, Director of  Lynn Sage Comprehensive Breast Center of Northwestern Memorial Hospital

Kirsten Anderson, MD, Aetna

Jeffrey Huff, PhD, Abbott Molecular

Kay Wissmann, Director, Government Affairs, Breast Cancer Network of Strength

4:45 – 5:00

Conclusion of Summit